If You Invested $1,000 in Moderna In January, This Is How Much You'd Have Now
Without having a crystal ball back in January, it would have been nearly impossible to predict the kind of year that Moderna (NASDAQ: MRNA) was going to have. COVID-19 was still in its very early stages of spreading and it wasn't until March 11 that the World Health Organization officially declared a pandemic. And now, with Moderna as one of the leaders in developing a coronavirus vaccine, it's evolved from a relatively unknown stock to a household name hogging all the headlines.
The company hopes to bring in billions of dollars in revenue for its two-dose vaccine candidate, mRNA-1273, which takes a novel mRNA approach. The treatment appears to be on the cusp of receiving emergency use authorization (EUA) from the Food and Drug Administration (FDA), which is convening an advisory committee to evaluate it next week. Its phase 3 study shows the vaccine candidate is up to 94.1% effective in preventing COVID-19. It's been a landmark year for Moderna and below we'll look at just how much you would have made from investing a modest sum at the start of the year. And more importantly, we'll determine whether Moderna is still a good buy today.
Image source: Getty Images.
Source Fool.com
